New drug aims to save lives in severe respiratory failure

NCT ID NCT07208591

Recruiting now Disease control Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests an experimental drug called STSA-1002 in 406 adults with acute respiratory distress syndrome (ARDS) caused by a viral infection. Participants receive either the drug or a placebo added to standard care. The main goal is to see if the drug lowers the chance of death within 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STSA-1002 injection
What this could lead to: If successful, STSA-1002 could become a new treatment to reduce deaths and speed recovery in patients with severe respiratory failure from viral infections.
What could go wrong: This is still an experimental drug. Even in Phase 3, it may not prove better than placebo, and side effects are possible. Results may not apply to all ARDS causes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

Contacts and locations

Locations

China-Japan Friendship Hospital
RECRUITING

Beijing, Beijing Municipality, 100029, China
Dazhou Central Hospital
RECRUITING

Dazhou, Sichuan, 635099, China
Hangzhou First People's Hospital
RECRUITING

Hangzhou, Zhejiang, 310006, China
Henan Provincial People's Hospital
RECRUITING

Zhengzhou, Henan, 450003, China
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital
RECRUITING

Chengdu, Sichuan, 610072, China
The Affiliated Hospital of Zunyi Medical University
RECRUITING

Zunyi, Guizhou, 563000, China
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITING

Luoyang, Henan, 471099, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, 361003, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, 450052, China
The First Affiliated Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 51063, China
The Third Affiliated Hospital of Guangzhou Medical University
RECRUITING

Guangzhou, Guangdong, 510150, China
Weifang People's Hospital
RECRUITING

Weifang, Shandong, 261041, China
Wuhan Central Hospital
RECRUITING

Wuhan, Hubei, 430014, China
Xiangtan Central Hospital
RECRUITING

Xiangtan, Hunan, 411100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.